Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. Rojo F, et al. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24347552
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Albanell J, et al. Among authors: rojo f. Cancer Res. 2001 Sep 1;61(17):6500-10. Cancer Res. 2001. PMID: 11522647
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Albanell J, et al. Among authors: rojo f. J Clin Oncol. 2002 Jan 1;20(1):110-24. doi: 10.1200/JCO.2002.20.1.110. J Clin Oncol. 2002. PMID: 11773160 Clinical Trial.
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J. Matar P, et al. Among authors: rojo f. Clin Cancer Res. 2004 Oct 1;10(19):6487-501. doi: 10.1158/1078-0432.CCR-04-0870. Clin Cancer Res. 2004. PMID: 15475436
490 results